Shots: Recursion to receive $30M as up front, $50M as equity investment, ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more […]readmore
Tags : Fibrotic Diseases
Shots: • The companies enter into a collaboration to conduct a study assessing the combination of Innovent’s Tyvyt (sintilimab injection) and Sirnaomics’ RNAi drug candidate STP705 (cotsiranib) in advanced cancers […]readmore
Shots: Pliant to receive $80M including upfront & equity investment and eligible to receive development, regulatory and commercial milestones with royalties on sales. Novartis to get exclusive WW license for […]readmore
Shots: Tum Bio to receive $1M upfront, up to $73M milestones and royalties on sales. Chiesi to get worldwide development and commercialization rights & will be responsible for its clinical […]readmore